S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:ABMD

Abiomed - ABMD Stock Forecast, Price & News

$381.02
0.00 (0.00%)
(As of 01/3/2023)
Add
Compare
Today's Range
$381.02
$381.02
50-Day Range
$377.20
$381.30
52-Week Range
$219.85
$381.99
Volume
258 shs
Average Volume
611,028 shs
Market Capitalization
$17.18 billion
P/E Ratio
65.47
Dividend Yield
N/A
Price Target
$350.50

Abiomed MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
8.0% Downside
$350.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.79
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$747,420 Sold Last Quarter
Proj. Earnings Growth
19.21%
From $4.58 to $5.46 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

653rd out of 1,053 stocks

Surgical & Medical Instruments Industry

67th out of 105 stocks


ABMD stock logo

About Abiomed (NASDAQ:ABMD) Stock

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Receive ABMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter.

ABMD Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
10 Best Performing Stocks in November
This Monster Dividend Stock Isn't Done Growing
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Why Is Abiomed (ABMD) Up 1.2% Since Last Earnings Report?
Abiomed (ABMD) Q2 Earnings Top Estimates, Margins Down
FDA Approves Abiomed's Impella Low Profile Sheath
See More Headlines
Receive ABMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter.

ABMD Company Calendar

Last Earnings
10/27/2021
Today
2/02/2023
Next Earnings (Estimated)
2/02/2023
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ABMD
CUSIP
00365410
Employees
2,003
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$350.50
High Stock Price Forecast
$388.00
Low Stock Price Forecast
$300.00
Forecasted Upside/Downside
-8.0%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$136.51 million
Pretax Margin
31.76%

Debt

Sales & Book Value

Annual Sales
$1.03 billion
Cash Flow
$5.09 per share
Book Value
$33.03 per share

Miscellaneous

Free Float
43,964,000
Market Cap
$17.18 billion
Optionable
Optionable
Beta
1.40

Social Links


Key Executives

  • Mr. Michael R. MinogueMr. Michael R. Minogue (Age 56)
    Chairman, CEO & Pres
    Comp: $3.04M
  • Mr. Todd A. TrappMr. Todd A. Trapp (Age 52)
    Exec. VP & CFO
    Comp: $914.93k
  • Mr. Marc A. BeganMr. Marc A. Began (Age 56)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $818.64k
  • Mr. Andrew J. GreenfieldMr. Andrew J. Greenfield (Age 50)
    Exec. VP & Chief Commercial Officer
    Comp: $804.95k
  • Dr. David M. Weber Ph.D. (Age 62)
    Scientific & Technology Advisor
    Comp: $1.02M
  • Mr. Matthew T. Plano (Age 58)
    Exec. VP of Global Operations & Integration
  • Dr. Thorsten Siess Ph.D.
    Exec. VP & Chief Technology Officer
  • Ms. Ingrid Goldberg Ward
    Director of Investor Relations
  • Sarah Karr
    Communications Mang.
  • Mr. Michael G. Howley (Age 59)
    VP & GM of Global Sales













ABMD Stock - Frequently Asked Questions

Should I buy or sell Abiomed stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ABMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View ABMD analyst ratings
or view top-rated stocks.

What is Abiomed's stock price forecast for 2023?

7 equities research analysts have issued 12 month target prices for Abiomed's stock. Their ABMD share price forecasts range from $300.00 to $388.00. On average, they anticipate the company's stock price to reach $350.50 in the next year. This suggests that the stock has a possible downside of 8.0%.
View analysts price targets for ABMD
or view top-rated stocks among Wall Street analysts.

How have ABMD shares performed in 2023?

Abiomed's stock was trading at $381.02 at the beginning of 2023. Since then, ABMD shares have increased by 0.0% and is now trading at $381.02.
View the best growth stocks for 2023 here
.

When is Abiomed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our ABMD earnings forecast
.

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) announced its quarterly earnings results on Wednesday, October, 27th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.05. The medical equipment provider earned $248.10 million during the quarter, compared to analyst estimates of $248.06 million. Abiomed had a net margin of 24.84% and a trailing twelve-month return on equity of 14.77%. Abiomed's revenue for the quarter was up 18.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.01 earnings per share.
Read the conference call transcript
.

What is Michael R. Minogue's approval rating as Abiomed's CEO?

96 employees have rated Abiomed Chief Executive Officer Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among the company's employees.

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Block (SQ), Netflix (NFLX), Adobe (ADBE) and Salesforce (CRM).

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Who are Abiomed's major shareholders?

Abiomed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ronald Blue Trust Inc. (0.01%), Baillie Gifford & Co. (0.01%), DekaBank Deutsche Girozentrale (0.00%), FNY Investment Advisers LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Joseph Riccelli, Magdalena Yesil, Marc A Began, Martin P Sutter, Matthew T Plano, Michael R Minogue, Michael R Minogue, Paul Thomas and Todd A Trapp.
View institutional ownership trends
.

How do I buy shares of Abiomed?

Shares of ABMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $381.02.

How much money does Abiomed make?

Abiomed (NASDAQ:ABMD) has a market capitalization of $17.18 billion and generates $1.03 billion in revenue each year. The medical equipment provider earns $136.51 million in net income (profit) each year or $5.82 on an earnings per share basis.

How many employees does Abiomed have?

The company employs 2,003 workers across the globe.

Does Abiomed have any subsidiaries?
The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.
Read More
How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The official website for the company is www.abiomed.com. The medical equipment provider can be reached via phone at (978) 646-1400, via email at ir@abiomed.com, or via fax at 978-777-8411.

This page (NASDAQ:ABMD) was last updated on 2/2/2023 by MarketBeat.com Staff